Targeting the cancer kinome through polypharmacology
- 1 February 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 10 (2), 130-137
- https://doi.org/10.1038/nrc2787
Abstract
It is becoming clear that targeting individual kinases is not sufficient to block the growth of most cancers. This Perspective discusses some of the strategies being used to identify new therapeutic combinations of kinase targets. Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.Keywords
This publication has 97 references indexed in Scilit:
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinomaNature, 2009
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994